from pharmadata import pharmaverseadam
meta = pharmaverseadam.meta('adab')
print(f"Rows: {meta.number_rows:,} Columns: {meta.number_columns}")Rows: 6,430 Columns: 72adab
adab
Anti-Drug Antibody Analysis Dataset
Structure: One or more records per subject per analysis parameter per analysis timepoint
Variables
Show variable specs
shape: (72, 5)
| variable | label | type | mandatory | role |
|---|---|---|---|---|
| str | str | str | str | null |
| "STUDYID" | "Study Identifier" | "String" | "Yes" | null |
| "USUBJID" | "Unique Subject Identifier" | "String" | "Yes" | null |
| "SUBJID" | "Subject Identifier for the Study" | "String" | "Yes" | null |
| "SITEID" | "Study Site Identifier" | "String" | "No" | null |
| "ASEQ" | "Analysis Sequence Number" | "Int32" | "No" | null |
| "REGION1" | "Geographic Region 1" | "String" | "No" | null |
| "COUNTRY" | "Country" | "String" | "No" | null |
| "ETHNIC" | "Ethnicity" | "String" | "No" | null |
| "AGE" | "Age" | "Float64" | "No" | null |
| "AGEU" | "Age Units" | "String" | "No" | null |
| "SEX" | "Sex" | "String" | "No" | null |
| "RACE" | "Race" | "String" | "No" | null |
| "SAFFL" | "Safety Population Flag" | "String" | "No" | null |
| "TRT01P" | "Description of Planned Arm" | "String" | "No" | null |
| "TRT01A" | "Description of Actual Arm" | "String" | "No" | null |
| "TRTSDTM" | "Datetime of First Exposure to Treatment" | "Datetime" | "No" | null |
| "TRTSDT" | "Date of First Exposure to Treatment" | "Date" | "No" | null |
| "TRTEDTM" | "Datetime of Last Exposure to Treatment" | "Datetime" | "No" | null |
| "TRTEDT" | "Date of Last Exposure to Treatment" | "Date" | "No" | null |
| "ISSEQ" | "Sequence Number" | "Int32" | "No" | null |
| "ISTESTCD" | "Immunogenicity Test/Exam Short Name" | "String" | "No" | null |
| "ISTEST" | "Immunogenicity Test or Examination Name" | "String" | "No" | null |
| "ISCAT" | "Category for Immunogenicity Test" | "String" | "No" | null |
| "ISBDAGNT" | "Binding Agent" | "String" | "No" | null |
| "ISSTRESC" | "Character Result/Finding in Std Format" | "String" | "No" | null |
| "ISSTRESN" | "Numeric Results/Findings in Std. Units" | "Float64" | "No" | null |
| "ISSTRESU" | "Standard Units" | "String" | "No" | null |
| "ISSTAT" | "Completion Status" | "String" | "No" | null |
| "ISREASND" | "Reason Not Done" | "String" | "No" | null |
| "ISSPEC" | "Specimen Type" | "String" | "No" | null |
| "DTL" | "Drug Tolerance Level" | "Float64" | "No" | null |
| "MRT" | "Minimum Reportable Titer" | "Float64" | "No" | null |
| "VISITNUM" | "Visit Number" | "Float64" | "No" | null |
| "VISIT" | "Visit Name" | "String" | "No" | null |
| "VISITDY" | "Planned Study Day of Visit" | "Float64" | "No" | null |
| "EPOCH" | "Epoch" | "String" | "No" | null |
| "ISDTC" | "Date/Time of Collection" | "String" | "No" | null |
| "ISDY" | "Study Day of Visit/Collection/Exam" | "Float64" | "No" | null |
| "ISTPT" | "Planned Time Point Name" | "String" | "No" | null |
| "ISTPTNUM" | "Planned Time Point Number" | "Float64" | "No" | null |
| "PARAM" | "Parameter" | "String" | "No" | null |
| "PARAMCD" | "Parameter Code" | "String" | "No" | null |
| "PARCAT1" | "Parameter Category 1" | "String" | "No" | null |
| "AVAL" | "Analysis Value" | "Float64" | "No" | null |
| "AVALC" | "Analysis Value (C)" | "String" | "No" | null |
| "AVALU" | "Analysis Value Unit" | "String" | "No" | null |
| "BASETYPE" | "Baseline Type" | "String" | "No" | null |
| "BASE" | "Baseline Value" | "Float64" | "No" | null |
| "CHG" | "Change from Baseline" | "Float64" | "No" | null |
| "DTYPE" | "Derivation Type" | "String" | "No" | null |
| "ADTM" | "Analysis Datetime" | "Datetime" | "No" | null |
| "ADT" | "Analysis Date" | "Date" | "No" | null |
| "ADY" | "Analysis Relative Day" | "Float64" | "No" | null |
| "ATMF" | "Analysis Time Imputation Flag" | "String" | "No" | null |
| "AVISIT" | "Analysis Visit" | "String" | "No" | null |
| "AVISITN" | "Analysis Visit (N)" | "Float64" | "No" | null |
| "ATPT" | "Analysis Timepoint" | "String" | "No" | null |
| "APHASE" | "Phase" | "String" | "No" | null |
| "APHASEN" | "Phase (N)" | "Int32" | "No" | null |
| "APERIOD" | "Period" | "Float64" | "No" | null |
| "APERIODC" | "Period (C)" | "String" | "No" | null |
| "FANLDTM" | "First Datetime of Dose for Analyte" | "Datetime" | "No" | null |
| "FANLDT" | "First Date of Dose for Analyte" | "Date" | "No" | null |
| "FANLTM" | "First Time of Dose for Analyte" | "Time" | "No" | null |
| "FANLTMF" | "First Time of Dose for Analyte ImputeFL" | "String" | "No" | null |
| "NFRLT" | "Nom. Rel. Time from Analyte First Dose" | "Float64" | "No" | null |
| "AFRLT" | "Act. Rel. Time from Analyte First Dose" | "Float64" | "No" | null |
| "FRLTU" | "Rel. Time from First Dose Unit" | "String" | "No" | null |
| "ABLFL" | "Baseline Record Flag" | "String" | "No" | null |
| "ADABLPFL" | "Baseline ADA Eval. Param-Level Flag" | "String" | "No" | null |
| "ADPBLPFL" | "Post-Baseline ADA Eval. Param-Level Flag" | "String" | "No" | null |
| "ADAFL" | "ADA Population Flag" | "String" | "No" | null |
Examples
from great_docs import tbl_explorer
from pharmadata import pharmaverseadam
tbl_explorer(pharmaverseadam.adab.head(10))PolarsRows10Columns72 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
STUDYID str |
USUBJID str |
SUBJID str |
SITEID str |
ASEQ i32 |
REGION1 str |
COUNTRY str |
ETHNIC str |
AGE f64 |
AGEU str |
SEX str |
RACE str |
SAFFL str |
TRT01P str |
TRT01A str |
TRTSDTM dtime |
TRTSDT date |
TRTEDTM dtime |
TRTEDT date |
ISSEQ i32 |
ISTESTCD str |
ISTEST str |
ISCAT str |
ISBDAGNT str |
ISSTRESC str |
ISSTRESN f64 |
ISSTRESU str |
ISSTAT str |
ISREASND str |
ISSPEC str |
DTL f64 |
MRT f64 |
VISITNUM f64 |
VISIT str |
VISITDY f64 |
EPOCH str |
ISDTC str |
ISDY f64 |
ISTPT str |
ISTPTNUM f64 |
PARAM str |
PARAMCD str |
PARCAT1 str |
AVAL f64 |
AVALC str |
AVALU str |
BASETYPE str |
BASE f64 |
CHG f64 |
DTYPE str |
ADTM dtime |
ADT date |
ADY f64 |
ATMF str |
AVISIT str |
AVISITN f64 |
ATPT str |
APHASE str |
APHASEN i32 |
APERIOD f64 |
APERIODC str |
FANLDTM dtime |
FANLDT date |
FANLTM time |
FANLTMF str |
NFRLT f64 |
AFRLT f64 |
FRLTU str |
ABLFL str |
ADABLPFL str |
ADPBLPFL str |
ADAFL str |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | CDISCPILOT01 | 01-701-1015 | 1015 | 701 | 1 | NA | USA | HISPANIC OR LATINO | 63 | YEARS | F | WHITE | Y | Placebo | Placebo | 2014-01-02 00:00:00+00:00 | 2014-01-02 | 2014-07-02 23:59:59+00:00 | 2014-07-02 | None | ADA_BAB | Binding Antidrug Antibody | IMMUNOGENICITY | XANOMELINE | None | None | None | None | None | SERUM | None | None | None | None | None | None | None | None | None | None | ADA Duration (Weeks), Anti-XANOMELINE Antibody (1) | ADADUR1 | Anti-XANOMELINE Antibody | None | None | None | DOUBLE_BLINDED | None | None | None | None | None | None | None | OVERALL | 11111 | None | None | None | None | None | None | None | None | None | None | None | None | None | None | None | Y |
| 1 | CDISCPILOT01 | 01-701-1015 | 1015 | 701 | 2 | NA | USA | HISPANIC OR LATINO | 63 | YEARS | F | WHITE | Y | Placebo | Placebo | 2014-01-02 00:00:00+00:00 | 2014-01-02 | 2014-07-02 23:59:59+00:00 | 2014-07-02 | None | ADA_BAB | Binding Antidrug Antibody | IMMUNOGENICITY | XANOMELINE | None | None | None | None | None | SERUM | None | None | None | None | None | None | None | None | None | None | ADA Status of a patient, Anti-XANOMELINE Antibody (1) | ADASTAT1 | Anti-XANOMELINE Antibody | None | MISSING | None | DOUBLE_BLINDED | None | None | None | None | None | None | None | OVERALL | 11111 | None | None | None | None | None | None | None | None | None | None | None | None | None | None | None | Y |
| 2 | CDISCPILOT01 | 01-701-1015 | 1015 | 701 | 3 | NA | USA | HISPANIC OR LATINO | 63 | YEARS | F | WHITE | Y | Placebo | Placebo | 2014-01-02 00:00:00+00:00 | 2014-01-02 | 2014-07-02 23:59:59+00:00 | 2014-07-02 | 1 | ADA_BAB | Binding Antidrug Antibody | IMMUNOGENICITY | XANOMELINE | NEGATIVE | None | titer | None | None | SERUM | None | None | 3 | BASELINE | 1 | TREATMENT | 2014-01-01T23:30:00 | -1 | Pre-dose | -0.5 | ADA Status of a patient by Visit, Anti-XANOMELINE Antibody (1) | ADASTTV1 | Anti-XANOMELINE Antibody | None | MISSING | None | DOUBLE_BLINDED | None | None | None | 2014-01-01 23:30:00+00:00 | 2014-01-01 | -1 | None | BASELINE | 3 | Pre-dose | None | None | 1 | Period 01 | 2014-01-02 00:00:00+00:00 | 2014-01-02 | 00:00:00 | H | 0 | -0.0208333333333 | DAYS | Y | None | None | Y |
| 3 | CDISCPILOT01 | 01-701-1015 | 1015 | 701 | 4 | NA | USA | HISPANIC OR LATINO | 63 | YEARS | F | WHITE | Y | Placebo | Placebo | 2014-01-02 00:00:00+00:00 | 2014-01-02 | 2014-07-02 23:59:59+00:00 | 2014-07-02 | 1 | ADA_BAB | Binding Antidrug Antibody | IMMUNOGENICITY | XANOMELINE | NEGATIVE | None | titer | None | None | SERUM | 999 | 1.4 | 3 | BASELINE | 1 | TREATMENT | 2014-01-01T23:30:00 | -1 | Pre-dose | -0.5 | Anti-XANOMELINE Antibody, Titer Units (1) | BABXANOM | Anti-XANOMELINE Antibody | None | None | None | DOUBLE_BLINDED | None | None | None | 2014-01-01 23:30:00+00:00 | 2014-01-01 | -1 | None | BASELINE | 3 | Pre-dose | None | None | 1 | Period 01 | 2014-01-02 00:00:00+00:00 | 2014-01-02 | 00:00:00 | H | 0 | -0.0208333333333 | DAYS | Y | Y | None | Y |
| 4 | CDISCPILOT01 | 01-701-1015 | 1015 | 701 | 5 | NA | USA | HISPANIC OR LATINO | 63 | YEARS | F | WHITE | Y | Placebo | Placebo | 2014-01-02 00:00:00+00:00 | 2014-01-02 | 2014-07-02 23:59:59+00:00 | 2014-07-02 | None | ADA_BAB | Binding Antidrug Antibody | IMMUNOGENICITY | XANOMELINE | None | None | None | None | None | SERUM | None | None | None | None | None | None | None | None | None | None | Baseline Pos/Neg, Anti-XANOMELINE Antibody (1) | BFLAG1 | Anti-XANOMELINE Antibody | 0 | N | None | DOUBLE_BLINDED | None | None | None | None | None | None | None | OVERALL | 11111 | None | None | None | None | None | None | None | None | None | None | None | None | None | None | None | Y |
| 5 | CDISCPILOT01 | 01-701-1015 | 1015 | 701 | 6 | NA | USA | HISPANIC OR LATINO | 63 | YEARS | F | WHITE | Y | Placebo | Placebo | 2014-01-02 00:00:00+00:00 | 2014-01-02 | 2014-07-02 23:59:59+00:00 | 2014-07-02 | None | ADA_BAB | Binding Antidrug Antibody | IMMUNOGENICITY | XANOMELINE | None | None | None | None | None | SERUM | None | None | None | None | None | None | None | None | None | None | Treatment Emergent - Negative, Anti-XANOMELINE Antibody (1) | EMERNEG1 | Anti-XANOMELINE Antibody | 0 | N | None | DOUBLE_BLINDED | None | None | None | None | None | None | None | OVERALL | 11111 | None | None | None | None | None | None | None | None | None | None | None | None | None | None | None | Y |
| 6 | CDISCPILOT01 | 01-701-1015 | 1015 | 701 | 7 | NA | USA | HISPANIC OR LATINO | 63 | YEARS | F | WHITE | Y | Placebo | Placebo | 2014-01-02 00:00:00+00:00 | 2014-01-02 | 2014-07-02 23:59:59+00:00 | 2014-07-02 | None | ADA_BAB | Binding Antidrug Antibody | IMMUNOGENICITY | XANOMELINE | None | None | None | None | None | SERUM | None | None | None | None | None | None | None | None | None | None | Treatment Emergent - Positive, Anti-XANOMELINE Antibody (1) | EMERPOS1 | Anti-XANOMELINE Antibody | 0 | N | None | DOUBLE_BLINDED | None | None | None | None | None | None | None | OVERALL | 11111 | None | None | None | None | None | None | None | None | None | None | None | None | None | None | None | Y |
| 7 | CDISCPILOT01 | 01-701-1015 | 1015 | 701 | 8 | NA | USA | HISPANIC OR LATINO | 63 | YEARS | F | WHITE | Y | Placebo | Placebo | 2014-01-02 00:00:00+00:00 | 2014-01-02 | 2014-07-02 23:59:59+00:00 | 2014-07-02 | None | ADA_BAB | Binding Antidrug Antibody | IMMUNOGENICITY | XANOMELINE | None | None | None | None | None | SERUM | None | None | None | None | None | None | None | None | None | None | Treatment enhanced ADA, Anti-XANOMELINE Antibody (1) | ENHANC1 | Anti-XANOMELINE Antibody | 0 | N | None | DOUBLE_BLINDED | None | None | None | None | None | None | None | OVERALL | 11111 | None | None | None | None | None | None | None | None | None | None | None | None | None | None | None | Y |
| 8 | CDISCPILOT01 | 01-701-1015 | 1015 | 701 | 9 | NA | USA | HISPANIC OR LATINO | 63 | YEARS | F | WHITE | Y | Placebo | Placebo | 2014-01-02 00:00:00+00:00 | 2014-01-02 | 2014-07-02 23:59:59+00:00 | 2014-07-02 | None | ADA_BAB | Binding Antidrug Antibody | IMMUNOGENICITY | XANOMELINE | None | None | None | None | None | SERUM | None | None | None | None | None | None | None | None | None | None | First Post Dose Positive Datetime, Anti-XANOMELINE Antibody (1) | FPPDTM1 | Anti-XANOMELINE Antibody | None | None | None | DOUBLE_BLINDED | None | None | None | None | None | None | None | OVERALL | 11111 | None | None | None | None | None | None | None | None | None | None | None | None | None | None | None | Y |
| 9 | CDISCPILOT01 | 01-701-1015 | 1015 | 701 | 10 | NA | USA | HISPANIC OR LATINO | 63 | YEARS | F | WHITE | Y | Placebo | Placebo | 2014-01-02 00:00:00+00:00 | 2014-01-02 | 2014-07-02 23:59:59+00:00 | 2014-07-02 | None | ADA_BAB | Binding Antidrug Antibody | IMMUNOGENICITY | XANOMELINE | None | None | None | None | None | SERUM | None | None | None | None | None | None | None | None | None | None | Treatment induced ADA, Anti-XANOMELINE Antibody (1) | INDUCD1 | Anti-XANOMELINE Antibody | 0 | N | None | DOUBLE_BLINDED | None | None | None | None | None | None | None | OVERALL | 11111 | None | None | None | None | None | None | None | None | None | None | None | None | None | None | None | Y |